- TLDR Biotech
- Archive
- Page -117
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | September 3 - 4, 2025
🧬 FDA publishes (heavily redacted) CRLs in transparency effort, Atlas Venture's new $400M fund, MindMed's new Ph2 LSD data in generalized anxiety disorder, Judge order Harvard funding reinstatement from Trump admin, an allogeneic CAR-T first for MS in Nebraska (first patient dosed), liver injury risks pushes FDA decision for Agios' Pyrukynd (mitapivat) for thalassaemia back to December, RFK Jr. goes on pharma offensive (again) and spouts mRNA misinformation (again)
Biotech & Pharma Updates | September 2 - 3, 2025
🧬 Treeline Biosciences $200M Series A extension, Galvanize's $100M oversubscribed Series C, Pfizer + Valneva's positive data from third annual Lyme disease booster, Novartis expands RNA collab with Chinese-biotech Argo (up to $5B), big pharma defends pandemic-era Warp Speed initiative as Trump admin scrutiny builds, Kite Pharma ends up to $2.3B collab on off-the-shelf cell therapies with Shoreline Biosciences
Biotech & Pharma Updates | September 1 - 2, 2025
🧬 Amgen's $600M R&D investment in California, CHARM Therapeutics nabs $80M Series B to power menin inhibitor ambitions, Merck & Co.'s oral PCSK9 inhibitor lands another Ph3 win, Novartis brings on Arrowhead's preclinical Parkinson's siRNA for $200M upfront + $2B biobucks, Eli Lilly ditches pair of naperiglipron (oral obesity therapy) Ph2 trials due to "strategic business reasons", Paul Offit ousted from HHS (outspoken RFK Jr. critic and member of FDA's vaccine advisory committee)
Biotech & Pharma Updates | August 28 - September 1, 2025
🧬 Novo Nordisk Wegovy bests Eli Lilly Zepbound in real world study on cardiovascular risk, Eli Lilly's DTC push in China with JD Health partnerships, Fosun gains Greater China rights to Accro Bioscience's TYK2/JAK1 inhibitor, Eli Lilly's pirtobrutinib lands UK approval for in relapsed blood cancers, J&J ditches rheumatoid arthritis angle for FcRn blocker nipocalimab after disappointing mid-stage results, University of Michigan sues AstraZeneca regarding FluMist contract renewal dispute
Biotech & Pharma Updates | August 27 - 28, 2025
🧬 Novo Nordisk's up to $550M RNA-obesity play with Replicate Biosciences, Teva reveals first obesity-targeting copycat GLP-1, protein degrader biotech Plexium raises $60M, Ascletis Pharma's touts promising Ph1b ascending dose study for obesity pill hopeful, Fresenius and Charles River Labs spearhead 18-partner effort for faster CAR-T production, Outlook Therapeutics' handed FDA CRL for wet AMD hopeful (second time), CDC director chaos continues
Biotech & Pharma Updates | August 26 - 27, 2025
🧬 Biopharma can't get enough of Chinese assets with H1 2025 spending already blowing past all of 2024, AstraZeneca and Eli Lilly plan major new site builds in Virginia (spurred by governmental incentives), Wugen raises $115M for "off-the-shelf" cell therapy ambitions, Eli Lilly's Verzenio delivers positive late-stage results in more common breast cancer, Massachusetts R&D & manufacturing jobs fell in 2024, CDC director ousted over vaccine regulations
Biotech & Pharma Updates | August 25 - 26, 2025
🧬 Regeneron preps FDA approval bid after siRNA cemdisiran Ph3 generalized myasthenia gravis results, Summit & Akeso report promising PD-1xVEGF bispecific Ph3 results (overall survival benefit), Novartis & BioArctic up to $772M neurodegenerative drug discovery pact, Bayer commits $43M expansion to Veracruz (Mexico) API site, rumors abound that CDC/HHS may outright ban COVID-19 vaccines
Biotech & Pharma Updates | August 24 - 25, 2025
🧬 AbbVie's $1.2B psychedelic play, RNA-based Arnatar launches with $52M, argenx preps approval bid after positive Ph3 Vyvgart results in generalized myasthenia gravis, Royalty Pharma buys part of BeOne's Imdelltra royalty stream (paid by Amgen for ex-China sales), another cell therapy biotech closes shop, FDA suspends Valneva’s chikungunya shot over safety concerns
Biotech & Pharma Updates | August 21 - 24, 2025
🧬 Biotech IPO drought ending?, FDA pushes for "radical transparency" with daily "real-time" adverse event reporting, OpenAI and Retro Biosciences publish 50x stem cell reprogramming results, BeOne's Burkinsa tablet formulation approved by European Commission, Novo acquired Catalent plants faces mounting contamination issues, CDC cuts 600 employees, obesity markets hits a (negative) turning point
Biotech & Pharma Updates | August 20 - 21, 2025
🧬 Gilead gets into in-vivo CAR-T for $350M, J&J invests $2B in existing North Carolina FUJIFILM site, Sarepta refinances debts to 2030, AbbVie's Rinvoq delivers positive Ph3, FDA approves Ionis' RNA-targeting hereditary angioedema med, Trump admin to impose 15% base tariff on EU - likely affecting branded pharmaceuticals